Skip to content

Savara SVRA Current ratio

Current ratio at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
2.1×+0.4×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
4.9×+1.9×
Innoviva, Inc. logo
Innoviva, Inc.INVA
21.1×+18.7×
Theravance Biopharma logo
Theravance BiopharmaTBPH
13.1×+8.4×
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
3.1×+0.5×
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
1.2×-0.8×

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+236%
Enterprise value$1.19B+224%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×

Where this comes from

Calculated from Savara’s reported figures.

Based on the most recent quarter.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's current ratio?
Savara (SVRA) reported current ratio of 13.5× in Q1 2026.
How has Savara's current ratio changed year-over-year?
Savara's current ratio decreased by 9.7% year-over-year, from 14.9× to 13.5×.
What is the long-term trend for Savara's current ratio?
Over 5 years (2020 to 2025), Savara's current ratio has grown at a 2.6% compound annual growth rate (CAGR), from 10.4× to 11.8×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.